{"count": 8, "results": [{"_id": "34280895", "pmid": 34280895, "pmcid": "PMC8346180", "title": "Perioperative control of paroxysmal hypertension using esmolol with alpha-blockade in a child with a germline mutated paraganglioma", "journal": "Endocrinol Diabetes Metab Case Rep", "authors": ["Babiker A", "Al Hamdan W", "Kinani S", "Kazzaz Y", "Habeb A", "Al Harbi T", "Al Dubayee M", "Al Namshan M", "Attasi AA"], "date": "2021-07-19T00:00:00Z", "doi": "10.1530/EDM-20-0101", "meta_date_publication": "2021 Jul 19", "meta_volume": "2021", "meta_issue": "20-0101", "meta_pages": "", "score": 50265.062, "text_hl": "She was known to have @DISEASE_Asthma @DISEASE_MESH:D001249 @@@asthma@@@; hence, she developed serious @<m>DISEASE_Bronchial_Spasm</m> @DISEASE_MESH:D001986 @@@bronchospasm@@@ with @<m>CHEMICAL_Atenolol</m> @CHEMICAL_MESH:D001262 @@@atenolol@@@. ", "citations": {"NLM": "Babiker A, Al Hamdan W, Kinani S, Kazzaz Y, Habeb A, Al Harbi T, Al Dubayee M, Al Namshan M, Attasi AA. Perioperative control of paroxysmal hypertension using esmolol with alpha-blockade in a child with a germline mutated paraganglioma Endocrinol Diabetes Metab Case Rep. 2021 Jul 19;2021(20-0101):. PMID: 34280895", "BibTeX": "@article{34280895, title={Perioperative control of paroxysmal hypertension using esmolol with alpha-blockade in a child with a germline mutated paraganglioma}, author={Babiker A and Al Hamdan W and Kinani S and Kazzaz Y and Habeb A and Al Harbi T and Al Dubayee M and Al Namshan M and Attasi AA}, journal={Endocrinol Diabetes Metab Case Rep}, volume={2021}, number={20-0101}}"}}, {"_id": "28556385", "pmid": 28556385, "title": "Atenolol Versus Propranolol for Treatment of Infantile Hemangiomas During the Proliferative Phase: A Retrospective Noninferiority Study.", "journal": "Pediatr Dermatol", "authors": ["Bayart CB", "Tamburro JE", "Vidimos AT", "Wang L", "Golden AB"], "date": "2017-07-01T00:00:00Z", "doi": "10.1111/pde.13177", "meta_date_publication": "2017 Jul", "meta_volume": "34", "meta_issue": "4", "meta_pages": "413-421", "score": 50065.902, "text_hl": "Food and Drug Administration has approved for the condition, but concern about adverse effects, such as @<m>DISEASE_Bronchial_Spasm</m> @DISEASE_MESH:D001986 @@@bronchospasm@@@, @DISEASE_Hypoglycemia @DISEASE_MESH:D007003 @@@hypoglycemia@@@, and @DISEASE_Sleep_Wake_Disorders @DISEASE_MESH:D012893 @@@sleep disturbances@@@, has sparked interest in the use of alternative agents such as the selective @GENE_MS4A1 @GENE_931 @@@beta1@@@ antagonist @<m>CHEMICAL_Atenolol</m> @CHEMICAL_MESH:D001262 @@@atenolol@@@. ", "citations": {"NLM": "Bayart CB, Tamburro JE, Vidimos AT, Wang L, Golden AB. Atenolol Versus Propranolol for Treatment of Infantile Hemangiomas During the Proliferative Phase: A Retrospective Noninferiority Study. Pediatr Dermatol. 2017 Jul;34(4):413-421. PMID: 28556385", "BibTeX": "@article{28556385, title={Atenolol Versus Propranolol for Treatment of Infantile Hemangiomas During the Proliferative Phase: A Retrospective Noninferiority Study.}, author={Bayart CB and Tamburro JE and Vidimos AT and Wang L and Golden AB}, journal={Pediatr Dermatol}, volume={34}, number={4}, pages={413-421}}"}}, {"_id": "2878680", "pmid": 2878680, "title": "A comparative study on the ventilatory and haemodynamic effects of xamoterol and atenolol in asthmatic patients.", "journal": "Br J Clin Pharmacol", "authors": ["Lammers JW", "Müller ME", "Folgering HT", "van Herwaarden CL"], "date": "1986-11-01T00:00:00Z", "doi": "10.1111/j.1365-2125.1986.tb02940.x", "meta_date_publication": "1986 Nov", "meta_volume": "22", "meta_issue": "5", "meta_pages": "595-602", "score": 50064.465, "text_hl": "@<m>DISEASE_Bronchial_Spasm</m> @DISEASE_MESH:D001986 @@@Bronchospasm@@@ induced by @<m>CHEMICAL_Atenolol</m> @CHEMICAL_MESH:D001262 @@@atenolol@@@ 50 mg and @CHEMICAL_Xamoterol @CHEMICAL_MESH:D017307 @@@xamoterol@@@ 200 mg was completely reversed by inhalation of the @GENE_ADRB2 @GENE_154 @@@beta 2-adrenoceptor@@@ agonist @CHEMICAL_Terbutaline @CHEMICAL_MESH:D013726 @@@terbutaline@@@ to a cumulative dose of 4.0 mg.", "citations": {"NLM": "Lammers JW, Müller ME, Folgering HT, van Herwaarden CL. A comparative study on the ventilatory and haemodynamic effects of xamoterol and atenolol in asthmatic patients. Br J Clin Pharmacol. 1986 Nov;22(5):595-602. PMID: 2878680", "BibTeX": "@article{2878680, title={A comparative study on the ventilatory and haemodynamic effects of xamoterol and atenolol in asthmatic patients.}, author={Lammers JW and Müller ME and Folgering HT and van Herwaarden CL}, journal={Br J Clin Pharmacol}, volume={22}, number={5}, pages={595-602}}"}}, {"_id": "6127219", "pmid": 6127219, "title": "Asthma and beta-blockers.", "journal": "Eur J Clin Pharmacol", "authors": ["Lawrence DS", "Sahay JN", "Chatterjee SS", "Cruickshank JM"], "date": "1982-01-01T00:00:00Z", "doi": "10.1007/BF00609622", "meta_date_publication": "1982", "meta_volume": "22", "meta_issue": "6", "meta_pages": "501-9", "score": 50060.13, "text_hl": "@<m>CHEMICAL_Atenolol</m> @CHEMICAL_MESH:D001262 @@@Atenolol@@@ caused significantly (p less than 0.05) less @<m>DISEASE_Bronchial_Spasm</m> @DISEASE_MESH:D001986 @@@bronchospasm@@@ in terms of fewer @DISEASE_Status_Asthmaticus @DISEASE_MESH:D013224 @@@asthmatic@@@ attacks, more @DISEASE_Asthma @DISEASE_MESH:D001249 @@@asthma@@@-free days, less frequent sensations of moderate to very severe, wheeziness and less effect on the evening peak flow rate. ", "citations": {"NLM": "Lawrence DS, Sahay JN, Chatterjee SS, Cruickshank JM. Asthma and beta-blockers. Eur J Clin Pharmacol. 1982;22(6):501-9. PMID: 6127219", "BibTeX": "@article{6127219, title={Asthma and beta-blockers.}, author={Lawrence DS and Sahay JN and Chatterjee SS and Cruickshank JM}, journal={Eur J Clin Pharmacol}, volume={22}, number={6}, pages={501-9}}"}}, {"_id": "2439815", "pmid": 2439815, "title": "Bopindolol, pindolol, and atenolol in patients with chronic obstructive lung disease.", "journal": "J Cardiovasc Pharmacol", "authors": ["Schiess W", "Dorow P"], "date": "1986-01-01T00:00:00Z", "doi": "10.1097/00005344-198608006-00007", "meta_date_publication": "1986", "meta_volume": "8 Suppl 6", "meta_issue": "", "meta_pages": "S30-3", "score": 50059.812, "text_hl": "@CHEMICAL_bopindolol @CHEMICAL_MESH:C036007 @@@Bopindolol@@@ 1, 2, and 4 mg and @<m>CHEMICAL_Atenolol</m> @CHEMICAL_MESH:D001262 @@@atenolol@@@ 50 mg also exhibited a neutral effect on mean Raw. ", "citations": {"NLM": "Schiess W, Dorow P. Bopindolol, pindolol, and atenolol in patients with chronic obstructive lung disease. J Cardiovasc Pharmacol. 1986;8 Suppl 6():S30-3. PMID: 2439815", "BibTeX": "@article{2439815, title={Bopindolol, pindolol, and atenolol in patients with chronic obstructive lung disease.}, author={Schiess W and Dorow P}, journal={J Cardiovasc Pharmacol}, volume={8 Suppl 6}, pages={S30-3}}"}}, {"_id": "9813739", "pmid": 9813739, "title": "[Pharmacologic importance of the combination atenolol/nifedipine in hypertensive patients].", "journal": "Drugs", "authors": ["Carré A"], "date": "1998-01-01T00:00:00Z", "doi": "10.2165/00003495-199856002-00003", "meta_date_publication": "1998", "meta_volume": "56 Suppl 2", "meta_issue": "", "meta_pages": "23-30", "score": 50059.266, "text_hl": "Its cardioselective nature diminishes the risk of @<m>DISEASE_Bronchial_Spasm</m> @DISEASE_MESH:D001986 @@@bronchospasm@@@, an event commonly induced by this type of drug. ", "citations": {"NLM": "Carré A. [Pharmacologic importance of the combination atenolol/nifedipine in hypertensive patients]. Drugs. 1998;56 Suppl 2():23-30. PMID: 9813739", "BibTeX": "@article{9813739, title={[Pharmacologic importance of the combination atenolol/nifedipine in hypertensive patients].}, author={Carré A}, journal={Drugs}, volume={56 Suppl 2}, pages={23-30}}"}}, {"_id": "14627967", "pmid": 14627967, "title": "Routine beta-blockade in vascular surgery.", "journal": "Cardiovasc Surg", "authors": ["Torella F", "de Cossart L", "Dimitri SK", "Edwards PR"], "date": "2003-12-01T00:00:00Z", "doi": "10.1016/S0967-2109(03)00127-3", "meta_date_publication": "2003 Dec", "meta_volume": "11", "meta_issue": "6", "meta_pages": "459-63", "score": 50051.53, "text_hl": "Two @SPECIES_9606 @@@patients@@@ suffered @<m>DISEASE_Bronchial_Spasm</m> @DISEASE_MESH:D001986 @@@bronchospasm@@@ leading to discontinuation of @<m>CHEMICAL_Atenolol</m> @CHEMICAL_MESH:D001262 @@@atenolol@@@. ", "citations": {"NLM": "Torella F, de Cossart L, Dimitri SK, Edwards PR. Routine beta-blockade in vascular surgery. Cardiovasc Surg. 2003 Dec;11(6):459-63. PMID: 14627967", "BibTeX": "@article{14627967, title={Routine beta-blockade in vascular surgery.}, author={Torella F and de Cossart L and Dimitri SK and Edwards PR}, journal={Cardiovasc Surg}, volume={11}, number={6}, pages={459-63}}"}}, {"_id": "1973460", "pmid": 1973460, "title": "Do we need a new classification of beta-blockers?", "journal": "J Hum Hypertens", "authors": ["Kendall MJ"], "date": "1990-06-01T00:00:00Z", "meta_date_publication": "1990 Jun", "meta_volume": "4 Suppl 2", "meta_issue": "", "meta_pages": "27-9", "score": 50048.31, "text_hl": "The advent of relatively @GENE_MS4A1 @GENE_931 @@@beta 1@@@-selective beta-blockers, in particular @CHEMICAL_Metoprolol @CHEMICAL_MESH:D008790 @@@metoprolol@@@ and @<m>CHEMICAL_Atenolol</m> @CHEMICAL_MESH:D001262 @@@atenolol@@@, made it possible to achieve the therapeutic benefits of @GENE_MS4A1 @GENE_931 @@@beta 1@@@-blockade whilst reducing the unwanted effects of beta 2-blockade; which, in addition to causing less @<m>DISEASE_Bronchial_Spasm</m> @DISEASE_MESH:D001986 @@@bronchospasm@@@, also meant less impact on arterial vasodilatation and @GENE_INS @GENE_3630 @@@insulin@@@, @CHEMICAL_Glucose @CHEMICAL_MESH:D005947 @@@glucose@@@ and @CHEMICAL_Fatty_Acids_Nonesterified @CHEMICAL_MESH:D005230 @@@free fatty acid@@@ release. ", "citations": {"NLM": "Kendall MJ. Do we need a new classification of beta-blockers? J Hum Hypertens. 1990 Jun;4 Suppl 2():27-9. PMID: 1973460", "BibTeX": "@article{1973460, title={Do we need a new classification of beta-blockers?}, author={Kendall MJ}, journal={J Hum Hypertens}, volume={4 Suppl 2}, pages={27-9}}"}}]}